Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-01-04
2011-01-04
Whiteman, Brian (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
Reexamination Certificate
active
07863437
ABSTRACT:
The invention relates to oligomeric compounds (oligomers), which target PIK3CA mRNA in a cell, leading to reduced expression of PIK3CA. Reduction of PIK3CA expression is beneficial for the treatment of certain medical disorders, such as hyperproliferative diseases (e.g., cancer). The invention provides therapeutic compositions that include the oligomers and methods for modulating the expression of PIK3CA using said oligomers, including methods of treatment.
REFERENCES:
patent: 4914210 (1990-04-01), Levenson et al.
patent: 4962029 (1990-10-01), Levenson et al.
patent: 7087229 (2006-08-01), Zhao et al.
patent: 2003/0148985 (2003-08-01), Morrissey et al.
patent: 2004/0235773 (2004-11-01), Zhao et al.
patent: 2004/0248840 (2004-12-01), Hansen et al.
patent: 2005/0272682 (2005-12-01), Evers et al.
patent: 2006/0030536 (2006-02-01), Yu et al.
patent: 1222309 (2005-02-01), None
patent: WO2004/046160 (2004-06-01), None
patent: 2005091849 (2005-10-01), None
patent: WO2005/091849 (2005-10-01), None
patent: WO2007/031081 (2007-03-01), None
patent: WO2007/031091 (2007-03-01), None
patent: 2007107162 (2007-09-01), None
patent: 2007136758 (2007-11-01), None
patent: WO2008/034122 (2008-03-01), None
patent: WO2008/034123 (2008-03-01), None
patent: WO2008/053314 (2008-05-01), None
Broderick, D. et al., “Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas”. Cancer Research, vol. 64, pp. 5048-5050, 2004.
Kurreck et al., “Design of antisense oligonucleotides stabilized by locked nucleic acids”. Nucleic Acids Research, Vo.. 30, pp. 1911-1918, 2002.
International Search Report issued in PCT/DK2008/000418 and dated Jun. 8, 2009.
Akinc, et al., “A combinatorial library of lipid-like materials for delivery of RNAi therapeutics,” Nature Biotechnology, vol. 26, No. 5, pp. 561-569, 2008.
Freier & Altmann; “The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DAN:RNA duplexes,”Nucl. Acid Research, vol. 25, No. 22, pp. 4429-4443, 1997.
Hsieh, et al., “A library of siRNA duplexes targeting the phosphoinositide 3-kinase pathway: determinants of gene silencing for use in cell-based screens,” NAR, vol. 32, No. 3, pp. 893-901, 2004.
Manoharan, et al., “Novel Funictionalization of the Sugar Moiety of Nucleic Acids for Multiple Labeling in the Minor Groove,”Tetrahedron Letters, vol. 32, No. 49, pp. 7171-7174, 1991.
U.S. Appl. No. 60/977,409.
Meng, et al., “Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway,” Cellular Signalling, vol. 18, pp. 2262-2271, 2006.
Rychahou, et al., “Targeted Molecular Therapy of the PI3K Pathway: Therapeutic Significance of PI3K Subunit Targeting in Colorectal Carcinoma,”Annals of Surgery, vol. 243, pp. 833-844, 2006.
Samuels, et al., “Oncogenic PI3K and its role in cancer,”Curr. Opin. Oncol., vol. 18, pp. 77-82, 2006.
Uhlmann, Eugen, “Recent advances in the medicinal chemistry of antisense oligonucleotides,” Curr.Opinion in Drug Development, Vo. 3, No. 2, pp. 203-213, 2000.
Zhang, et al., “A Potential Strategy for Isoform-Specific Phosphatidylinositol 3-Kinase Targeted Therapy in Ovarian Cancer,”Cancer Biology and Therapy, vol. 3, No. 12, pp. 1283-1289, 2004.
Zhao, et al., “A New Platform for Oligonucleotide Delivery Utilizing the PEG Prodrug Approach,”Bioconjudate Chemistry, vol. 16, No. 4, pp. 758-766, 2005.
Zhao, et al.,“Delivery of G3139 using releasable PEG-linkers: Impact on pharmacokinetic profile and anti-tumor efficacy,”J. of Controlled Release, vol. 119, pp. 143-152, 2007.
Enzon Pharmaceuticals, Inc.
Lucas & Mercanti LLP
Santaris Pharma A/S
Whiteman Brian
LandOfFree
RNA antagonist compounds for the modulation of PIK3CA... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with RNA antagonist compounds for the modulation of PIK3CA..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RNA antagonist compounds for the modulation of PIK3CA... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2623267